| Dorica Nevin, PSYD | |
|
21 Waterville Rd, Avon, CT 06001-2097 | |
| (860) 284-0181 | |
| (860) 284-6804 |
| Full Name | Dorica Nevin |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 36 Years |
| Location | 21 Waterville Rd, Avon, Connecticut |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063781672 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 001590 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psychological Health And Development Associates Llc | 6103129333 | 3 |
News Archive
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.
Veridex, LLC today announced the publication of a new, investigational study published this week in Science Translational Medicine that lays the foundation for research that may potentially result in a blood test to determine imminent risk of heart attack within high-risk populations.
› Verified 9 days ago
| Entity Name | Psychological Health & Development Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144519968 PECOS PAC ID: 6103129333 Enrollment ID: O20160122000307 |
News Archive
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.
Veridex, LLC today announced the publication of a new, investigational study published this week in Science Translational Medicine that lays the foundation for research that may potentially result in a blood test to determine imminent risk of heart attack within high-risk populations.
› Verified 9 days ago
| Entity Name | Jd Psychological Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932573599 PECOS PAC ID: 0648576553 Enrollment ID: O20160302001487 |
News Archive
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.
Veridex, LLC today announced the publication of a new, investigational study published this week in Science Translational Medicine that lays the foundation for research that may potentially result in a blood test to determine imminent risk of heart attack within high-risk populations.
› Verified 9 days ago
| Entity Name | Wellqor Psychological Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063920841 PECOS PAC ID: 1658633292 Enrollment ID: O20180320001904 |
News Archive
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.
Veridex, LLC today announced the publication of a new, investigational study published this week in Science Translational Medicine that lays the foundation for research that may potentially result in a blood test to determine imminent risk of heart attack within high-risk populations.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dorica Nevin, PSYD 21 Waterville Rd, Avon, CT 06001-2097 Ph: (860) 284-0181 | Dorica Nevin, PSYD 21 Waterville Rd, Avon, CT 06001-2097 Ph: (860) 284-0181 |
News Archive
Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.
Veridex, LLC today announced the publication of a new, investigational study published this week in Science Translational Medicine that lays the foundation for research that may potentially result in a blood test to determine imminent risk of heart attack within high-risk populations.
› Verified 9 days ago
Elizabeth S Thayer, PHD CLINICAL PSYCHOL Psychologist Medicare: Not Enrolled in Medicare Practice Location: 40 Dale Road, Suite 201, Avon, CT 06001 Phone: 860-676-9350 Fax: 860-678-7178 | |
Judith Davidson, PHD Psychologist Medicare: May Accept Medicare Assignments Practice Location: 21 Waterville Rd, Avon, CT 06001 Phone: 860-674-2691 Fax: 860-677-6443 | |
Wendy F Habelow, PHD CLINICAL PSYCHOL Psychologist Medicare: Not Enrolled in Medicare Practice Location: 40 Dale Road, Suite 201, Avon, CT 06001 Phone: 860-676-9350 Fax: 860-678-7178 | |
Dr. Samuel Moy, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 7 Rexinger Ln, Avon, CT 06001 Phone: 860-704-6188 | |
Hsiao-ching Chu, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1 Darling Dr Ste 16, Avon, CT 06001 Phone: 860-798-4148 | |
Ted Scott Sewitch, PHD CLINICAL PSYCHOL Psychologist Medicare: Not Enrolled in Medicare Practice Location: 40 Dale Road, Suite 201, Avon, CT 06001 Phone: 860-676-9350 Fax: 860-678-7178 |